Skyrizi

Active Ingredient(s): Risankizumab-rzaa
FDA Approved: * April 23, 2019
Pharm Company: * ABBVIE INC
Category: Skin Care

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Skyrizi Overview

Risankizumab (trade name Skyrizi) is a humanized monoclonal antibody targeting interleukin 23A (IL-23A).[1] Risankizumab is part of a collaboration between Boehringer Ingelheim and AbbVie. Risankizumab has been approved in Europe, USA, Canada and Japan for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Clinical trials Psoriasis In a phase I clinical trial, thirty-nine patients received single-dose risankizumab, 18 of wh...

Read more Skyrizi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Risankizumab

Recent Skyrizi Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Skyrizi: (1 result)

Sorted by National Drug Code

• 0074-2042 SkyriziSkyrizi Kit by Abbvie Inc.

Other drugs which contain Risankizumab-rzaa or a similar ingredient: (1 result)

• RISANKIZUMAB-RZAA